These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus. Bonomini V; Vangelista A; Frascà GM; Nanni-Costa A; Borgnino LC Clin Nephrol; 1984 Sep; 22(3):121-6. PubMed ID: 6237815 [TBL] [Abstract][Full Text] [Related]
27. Diffuse proliferative lupus glomerulonephritis. Recovery from prolonged renal failure. Moore WS; Guggenheim SJ; Anderson RJ JAMA; 1980 Jul; 244(1):63-5. PubMed ID: 7382059 [TBL] [Abstract][Full Text] [Related]
28. [Long-term follow-up on the treatment of diffuse proliferative glomerulonephritis in patients with systemic lupus erythematosus]. Golan E; Weintal I; Bernheim J; Ben-Chetrit S; Bernheim J Harefuah; 2002 Apr; 141(4):324-8, 412. PubMed ID: 12017882 [TBL] [Abstract][Full Text] [Related]
29. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Euler HH; Guillevin L Ann Med Interne (Paris); 1994; 145(5):296-302. PubMed ID: 7985935 [TBL] [Abstract][Full Text] [Related]
30. [Plasmapheresis, an aid in the treatment of patients with active systematic lupus erythematosus?]. Houwert DA; Kater L; Struyvenberg A Ned Tijdschr Geneeskd; 1978 May; 122(19):678-81. PubMed ID: 148592 [No Abstract] [Full Text] [Related]
31. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Mok CC; To CH; Mak A; Ma KM Arthritis Rheum; 2005 Dec; 52(12):3997-4002. PubMed ID: 16320346 [TBL] [Abstract][Full Text] [Related]
32. Plasma exchange in the treatment of lupus nephritis. Moriconi L; Ferri C; Fanara G; Migliorini P; Vitali C; Cioni L; Gremignai G; Bombardieri S Int J Artif Organs; 1983 Jul; 6 Suppl 1():35-8. PubMed ID: 6642734 [TBL] [Abstract][Full Text] [Related]
34. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Adu D; Williams DG; Taube D; Vilches AR; Turner DR; Cameron JS; Ogg CS Q J Med; 1983; 52(208):471-87. PubMed ID: 6606818 [TBL] [Abstract][Full Text] [Related]
35. Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression. Leaker BR; Becker GJ; Dowling JP; Kincaid-Smith PS Clin Nephrol; 1986 May; 25(5):236-44. PubMed ID: 3720034 [TBL] [Abstract][Full Text] [Related]
36. Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus. Schneider M; Berning T; Waldendorf M; Glaser J; Gerlach U J Rheumatol; 1990 Jul; 17(7):900-7. PubMed ID: 2213756 [TBL] [Abstract][Full Text] [Related]
37. [Status of plasmapheresis and cyclosporin A in the treatment of systemic lupus erythematosus]. Graf N; Bambauer R; Jost W; Schäfer M Monatsschr Kinderheilkd; 1990 Jul; 138(7):395-8. PubMed ID: 2398909 [TBL] [Abstract][Full Text] [Related]
38. Diffuse proliferative lupus glomerulonephritis. Determination of prognostic significance of clinical, laboratory and pathologic factors. Magil AB; Ballon HS; Chan V; Lirenman DS; Rae A; Sutton RA Medicine (Baltimore); 1984 Jul; 63(4):210-20. PubMed ID: 6377004 [TBL] [Abstract][Full Text] [Related]
39. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. Stricker RB; Davis JA; Gershow J; Yamamoto KS; Kiprov DD J Rheumatol; 1992 Sep; 19(9):1469-73. PubMed ID: 1433019 [TBL] [Abstract][Full Text] [Related]